Dr. Elizabeth Yurth is the Co-Founder and Medical Director of Boulder Longevity Institute. Dr. Yurth is double-Board Certified in Physical Medicine & Rehabilitation and Anti-Aging/Regenerative Medicine. She has a Stanford-affiliated Fellowship in Sports and Spine Medicine, and a dual-Fellowship in Anti-Aging and Regenerative Medicine (FAARM) and Anti-Aging, Regenerative and Functional Medicine (FAARFM). As an athlete herself who has dealt with numerous injuries, Dr. Yurth is thrilled to share with her clients all the innovative, life-changing treatments that are on the cutting-edge of medicine
Elizabeth Yurth, MD
Continue exploring related topics.
VIEW ALLIn this bonus episode from the MM15 Virtual Summit, Dr. Seeds addresses an important question around the use of GLP-1s for metabolic balancing in patients who do not need to lose weight. He shares his perspective on what may be considered microdosing, along with the clinical thought process he uses when determining appropriate dosing in these more nuanced cases.
Additional questions from the MM15 Virtual Summit can be found in our accompanying article here: [insert article link]
Access the full MM15 Course here: Mastermind 15 on Aesthetics
The Limits of Alternative Peptide Delivery
Dr. Seeds reviews oral, sublingual, and transdermal peptide delivery, and explains why subcutaneous injection remains the gold standard for most peptides. (Question Link)
A Deeper Look at the RAAS System
Dr. Seeds uses this Rabbit Holes episode to build on Journal Club Episode 87, revisiting the renin-angiotensin-aldosterone system and its broader role in cellular signaling. The discussion focuses on receptor balance, local tissue effects, and the mechanisms linking RAS disruption to inflammation, fibrosis, and mitochondrial stress.(Article Link)
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Dr. Seeds unpacks how RAS receptor balance drives inflammation, fibrosis, mitochondrial dysfunction, and tissue remodeling, far beyond its classical role in blood pressure regulation. (Article Link)
1. SSRI tapering resistance, anxiety during weaning (0:40)
2. Progressive multifocal dystonia (13:27)
3. Complex type 2 diabetes case in a lean, athletic patient (28:32)